Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536991 · ClinicalTrials.gov registry record · Phase 1
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00536991 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 51 participants.
The verdict
NCT00536991, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Therapeutic Hydrocortisone
- OTHER Pharmacological Study
- DRUG Ketoconazole
- DIETARY_SUPPLEMENT Calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536991
The ClinicalTrials.gov registry entry for NCT00536991 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00536991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00536991 about?
NCT00536991 is a clinical study titled "Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer". This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and gr...
What is the current status of trial NCT00536991?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2006-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00536991?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Hydrocortisone (DRUG), Pharmacological Study (OTHER), Ketoconazole (DRUG), Calcitriol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00536991?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.